Published in Transl Res on June 11, 2015
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol (2017) 0.82
Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. Oncotarget (2016) 0.78
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther (2016) 0.75
Targeted Therapies for the Treatment of Non-Small-Cell Lung Cancer: Monoclonal Antibodies and Biological Inhibitors. Hum Vaccin Immunother (2016) 0.75
Ipilimumab-Induced Enteritis without Colitis: A New Challenge. Case Rep Oncol (2016) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 6.07
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg (2011) 2.21
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA (2014) 2.13
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun (2010) 1.57
Hemophilia A induced by ipilimumab. N Engl J Med (2011) 1.55
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab (2013) 1.42
Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol (2011) 1.37
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother (2009) 1.36
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother (2009) 1.36
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res (2011) 1.35
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer (2014) 1.32
Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med (2009) 1.30
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med (2014) 1.29
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges (2010) 1.25
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother (2010) 1.24
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res (2015) 1.20
Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab (2014) 1.19
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol (2013) 1.15
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol (2014) 1.11
A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother (2013) 1.06
Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res (2014) 1.05
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol (2014) 1.05
Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology (2008) 1.05
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol (2011) 1.04
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat (2013) 1.03
Kidney injuries related to ipilimumab. Invest New Drugs (2014) 1.03
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother (2008) 1.01
Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol (2014) 1.00
Ipilimumab-induced immune-related renal failure--a case report. Anticancer Res (2012) 1.00
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. J Clin Oncol (2014) 1.00
Ipilimumab-induced perforating colitis. J Clin Gastroenterol (2013) 1.00
Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist (2012) 0.99
Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol (2015) 0.98
Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res (2012) 0.98
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol (2012) 0.98
Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther (2014) 0.98
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol (2011) 0.96
Ipilimumab-induced colonic perforation. J Surg Case Rep (2014) 0.96
Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer (2014) 0.95
Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit (2014) 0.95
Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study. Cancer Invest (2013) 0.91
Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother (2009) 0.90
Ipilimumab granulomatous interstitial nephritis. Am J Ther (2015) 0.89
Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs (2013) 0.88
Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol (2013) 0.88
Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep (2014) 0.87
Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J (2013) 0.87
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis (2011) 0.86
A review of novel therapies for melanoma. Am J Clin Dermatol (2014) 0.86
Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology (2014) 0.86
New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat (2014) 0.85
Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review. Jpn J Clin Oncol (2015) 0.85
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res (2013) 0.85
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler (2014) 0.84
Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs (2012) 0.82
Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clin Neurol Neurosurg (2014) 0.81
Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol (2015) 0.81
Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol (2013) 0.79
Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol (2014) 0.79
Ipilimumab immune-related adverse reactions: a case report. S D Med (2013) 0.79
Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg (2014) 0.79
Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol (2012) 0.79
A case report of orbital inflammatory syndrome secondary to ipilimumab. Ophthal Plast Reconstr Surg (2015) 0.79
Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression". Ophthal Plast Reconstr Surg (2013) 0.76
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther (2013) 0.76
Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother (2015) 0.76
Ipilimumab-associated Sweet syndrome in a melanoma patient. J Am Acad Dermatol (2014) 0.76
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis. NDT Plus (2009) 0.76
Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res (2015) 0.87